TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Tri…

High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs. Socías ME, Ti L, Dong H, Shoveller J, Kerr T, Montaner J, Milloy MJ. HIV Med…

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries Ghinea, Narcyz et al. The Lancet , Volume 389 , Issue 10075 , 1268 - 1272 http://www.thelancet.com/journals/lancet/article/PIIS0140-…

Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101. Stelma F, van der Ree MH, Sinnige MJ, Brown A, Swadling L, de Vree JM, Willemse SB, van der Valk M, Grint P, Neben S…

Hannover. Mit dem Hepatitis C-Virus (HCV) sind weltweit etwa 160 Millionen Menschen infiziert. Obwohl es neue Therapeutika gibt, ist die Virusinfektion eine der häufigsten Ursachen für Lebertransplantationen, denn die neuen Medikamente sin…

Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions. Duffell EF, Hedrich D…